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Perspective

Mitofusin activation enhances
mitochondrial motility and promotes
neuroregeneration in CMT2A
Gerald W. Dorn II*
Human brains represent only 2% of body
mass, but their high relative metabolic
activity accounts for ~20% of total body
adenosine triphosphate (ATP) consumption.
ATP generated by neuronal mitochondria
fuels nerve signaling and homeostatic repair.
In the peripheral nervous system, which
has greater capacity for regeneration after
physical, toxic or genetic injury than the
central nervous system, ATP also powers
actin polymerization/depolymerization for
growth cone formation and axon extension.
Mitochondrial ATP generation is therefore a
central component of neuronal functioning
in the central and peripheral nervous
systems.
The contextual roles of neuronal
mitochondria are largely determined by two
factors, the fitness of individual organelles
and their localization within host neurons.
The role of mitochondrial fitness is widely
acknowledged: healthy mitochondria
perform their ATP-producing function
without compromising host neurons,
whereas damaged mitochondria in which the
respiratory chain is partially uncoupled from
ATP production elaborate cytotoxic reactive
oxygen species (ROS) that both damage the
host neuron and can activate programmed
cell death pathways. By comparison,
the role of mitochondrial transport and
localization has only recently become widely
appreciated: almost all ~1000 mitochondrial
proteins (i.e. except the 13 respiratory chain
proteins encoded by the mitochondrial
genome) are encoded by nuclear genes
and synthesized by host cell ribosomes.
Therefore, mitochondrial biogenesis takes
place primarily in neuronal soma and newly
formed mitochondria in the cell body are
actively directed to distal areas of neuronal
activity, such as synapses and growth
cones. The unique architecture of neurons,
especially long motor neurons innervating
upper and lower extremities, requires that
mitochondria traverse approximately 1 meter
of axon length from neuronal soma in the
spine to peripheral neuromuscular junctions.
Damaged or senescent mitochondria in
synapses or growth buds likewise require
export for mitophagic elimination, which
is necessary to prevent mitochondrial-

mediated ROS cytotoxicity at distal nerves.
Thus, an interruption in mitochondrial
transport might be as consequential to
neuronal health as, and can contribute to,
impaired mitochondrial fitness. Recently,
Franco et al. (2020) demonstrated that
directly enhancing mitochondrial trafficking
within neuronal axons helps regenerate
peripheral nerve damage in a mouse model
of the rare sensorimotor neuropathy,
Charcot-Marie-Tooth disease type 2A
(CMT2A). These studies provide critical in
vitro and in vivo support mechanistically
linking mitochondrial trafficking to neuronal
regeneration.
Tw o g e n e t i c n e u r o p a t h i e s s e r v e a s
prototypical neurodegenerative diseases
having mitochondrial dysfunction: Familial
amyotrophic lateral sclerosis caused by
mutations of superoxide dismutase 1 (SOD1)
is an example of loss of mitochondrial fitness
(Wong et al., 1995), in this case precipitated
by increased neuronal ROS levels. CMT2A
caused by mutations of mitofusin 2 (MFN2)
is an example of interrupted mitochondrial
transport (Baloh et al., 2007), although the
precise mechanism by which dysfunction
of a mitochondrial fusion protein impairs
mitochondrial trafficking remains unclear.
MFN2 and closely related MFN1 were
originally described as proteins mediating
mammalian outer mitochondrial membrane
fusion (Dorn, 2019). MFN2 also plays
important roles in mitophagy (the selective
elimination of damaged mitochondria via
autophagy pathways) (Chen and Dorn,
2013) and axonal mitochondrial transport
(Rocha et al., 2018). The observations
that mitochondrial motility is impaired
in CMT2A caused by MFN2 mutations
(Baloh et al., 2007), and that CMT2Aassociated mitochondrial dysmotility can
be reversed by small molecule mitofusin
activators (Rocha et al., 2018), suggested
that pharmacological activation of
endogenous normal MFN1 and MFN2 might
overcome mutant MFN2 suppression of
normal mitofusin functioning in autosomal
dominant CMT2A. While conceptually
simple, the putative mechanistic link
between mitofusin dysfunction and
disease progression in CMT2A has at least

4 degrees of separation: (1) MFN1/MFN2mediated mitochondrial fusion and motility
a re s u p p re s s e d by d o m i n a nt C M T 2 A
MFN2 mutants; (2) transport of healthy
mitochondria to, and damaged mitochondria
away from, neuromuscular junctions is
diminished; (3) neuromuscular signaling is
consequently impaired; (4) motor nerves
die back from muscles; and (5) muscle mass
decreases due to neurogenic atrophy. This
pathophysiological complexity confounded
expectations of whether mitofusin activation
could reverse disease in vivo.
In testing the idea of activating endogenous
normal mitofusins in CMT2A Franco et al.
(2020) developed three major objectives.
The first was to assess the relevance of
mitofusin activation in human CMT2A by
replicating in human CMT2A patient neurons
previous observations that mitofusin
activation can reverse mitochondrial
dysmotility in mouse CMT2A nerve axons
(Franco et al., 2016; Rocha et al., 2018; Dang
et al., 2020). Because iPSC-derived neurons
lose characteristic CMT2A mitochondrial
phenotypes (e.g. fragmentation from loss
of fusion and stasis from loss of motility),
Franco et al. (2020) used microRNA-mediated
neuronal conversion to directly reprogram
CMT2A patient dermal fibroblasts having four
different MFN2 mutations into HB9/MNX1positive motor neurons. Reprogramming
efficiency was > 90% neurons (β-III tubulin
positive) and > 85% motor neurons (HB9
positive) in both normal and CMT2A
cells. Compared to reprogrammed motor
neurons from multiple normal subjects, all
four CMT2A motor neuron lines exhibited
hallmark mitochondrial fragmentation
(loss of fusion), depolarization (impaired
respiratory function), and dysmotility
(measured as the proportion and velocity
of motile mitochondria). Notwithstanding
different genetic mechanisms for MFN2
dysfunction (two mutations within the
MFN2 GTPase domain and two within the
MFN2 coiled-coiled hydrophobic core),
all four reprogrammed CMT2A motor
neuron lines responded to addition of
a small molecule mitofusin activator by
normalizing mitochondrial morphology,
polarization status and motility. Thus,
human CMT2A neurons, like CMT2A mouse
neurons, respond to mitofusin activation by
reversing prototypical mitochondrial disease
phenotypes. Moreover, in this small sample
the benefit on mitochondria appeared to be
agnostic to causal MFN2 mutation.
The second goal of Franco et al. (2020)
was to establish efficacy in an in vivo
mouse CMT2A model similar to the human
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condition. Because there were no published
CMT2A mouse models that reproduce
the time course of disease progression,
pattern of neuromuscular dysfunction,
neuroelectrophysiological features, and
histological/ultrastructural characteristics of
human CMT2A in the absence of confounding
developmental defects (Dorn, 2020), they
generated a new model by combining motor
neuron specific Mnx1-Cre and flox-stop
human MFN2-T105M transgenes (Franco
et al., 2020). The resulting mice express
mutant human (h) MFN2 T105M in mouse
motor neurons, but the Cre that evokes
mutant MFN2 expression is extinguished
after the first week of life, and is therefore
not a continuing variable. Paralleling the
human pattern of childhood onset with
disease progression into young adulthood,
CMT2A hMFN2 T105M mice were normal
up to 10 weeks of age and then exhibited
a progressive decline in neuromuscular
function (measured as RotaRod latency)
from 20 to 30 weeks, after which the
disease stabilized. Human CMT2A is clinically
distinguished from more common CMT1
by neuroelectrophysiologic testing showing
decreased amplitude of compound muscle
action potentials (reflecting loss of neurons)
without decreased ner ve conduction
velocity (because in CMT2A there is no loss
of myelin); this was also recapitulated in
MFN2 T105M mice. Finally, the characteristic
histological and ultrastructural features of
CMT2A were reproduced in hMFN2 T105M
mice. Remarkably, daily intramuscular
injection of the mitofusin activator transMiM111 to mice having the full-fledged
CMT2A phenotype reversed all of these
abnormalities within 8 weeks (Franco et al.,
2020).
The final goal of Franco et al. (2020) was
to elucidate mechanisms for observed
CMT2A phenotype reversal after mitofusin
activation. As currently understood, the
pathophysiology of forearm and foreleg
neuromuscular degeneration caused by
loss-of-function MFN2 mutations in CMT2A
consists of the following: (1) genetic
mitochondrial dysfunction and dysmotility
leads to a dearth of healthy mitochondria
at neu ro m u sc ular j un c ti o n s ; ( 2 ) th i s
compromises neuromuscular signaling and
evokes distal neuron die-back; and 3. the
end result is neurogenic muscular atrophy
(Figure 1). If this is correct, then restoration
of function in mitofusin activator-treated
CMT2A mice implies that the neurons which
had previously died back were regenerated,
thus reestablishing neuromuscular integrity.
Alternately, restoration of mitochondrial
fusion alone might have engendered

Figure 1 ｜ Schematic depiction of relationship between mitochondrial transport, neuron die-back,
and neuron regeneration in CMT2A.
Normal nerves (top) have bidirectional mitochondrial transport that delivers healthy organelles to
and removes damaged organelles from, nerve termini. In CMT2A nerves (middle) interruption of
distal mitochondrial transport impairs nerve function and repair, prompting dying back of the termini.
Restoration of mitochondrial transport by activated mitofusins (bottom) promotes nerve regeneration
that reverses in vivo neuromuscular dysfunction. CMT2A: Charcot-Marie-Tooth disease type 2A.

neuroprotective effects. However, in support
of a connection between mitochondrial
trafficking and neuronal regeneration,
enhancing mitochondrial motility by
genetically ablating the neuronal anchoring
protein syntaphilin was previously shown to
promote neuronal regrowth after physical
injury (Zhou et al., 2016).
Franco et al. (2020) performed a series of
in vivo and in vitro experiments to more
fully understand the connection between
m i t o f u s i n a c t i va t i o n , m i t o c h o n d r i a l
tra n s p o r t/l o ca l i zati o n, a nd neuro na l
regeneration. Reasoning that impaired
mitochondrial trafficking to neuromuscular
junctions and neuronal die-back in CMT2A
would result in a decreased mitochondrial
occupancy of junctional synapses and a
reduced total number of junctional synapses,
respectively, they used immunohistology
to quantify junctional synapses (antiacetylcholine receptor) and their resident
mitochondria (anti-cytochrome oxidase IV)
in mouse foreleg muscles. Consistent with
a link between mitochondrial trafficking
and neuronal regrowth, tibialis muscles
of vehicle-treated CMT2A mice had fewer
than half the normal number of junctional
synapses per muscle myocyte, and only ~half
the normal density of mitochondria within
those synapses; mitofusin activation reversed
both of those abnormal metrics (Franco et
al., 2020).
The above result supported the thesis
that mitofusin activation promotes neuron
regeneration in CMT2A, but the in vivo
data were entirely correlative. Moreover,
the observed relationship between
mitochondrial localization within junctional
synapses and enhanced mitochondrial
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motility is inferential. Therefore, Franco et
al. (2020) isolated dorsal root ganglion (DRG)
neurons from mice carrying the hMFN2
T105M flox-stop allele, activated the mutant
MFN2 transgene in vitro using adenoviral
Cre, and measured DRG outgrowth in
the presence or absence of the mitofusin
activator. (Note, in vitro activation of hMFN2
T105M with adeno-Cre was necessary for this
experiment because DRGs contain sensory
neurons and the MNX1/HB9 promoter used
in vivo drives predominantly motor neuron
expression.) The CMT2A DRG platform
permitted live cell studies of mitochondrial
aspect ratio (an indirect measure of fusion),
mitochondrial motility and residency within
axonal termini (linking axonal transport to
distal neuron localization), and axon growth/
branching (a metric of axon regeneration
after isolation and plating), which was not
possible in fixed tissue. Mitofusin activation
strikingly improved each of the measured
endpoints, normalizing mitochondrial aspect
ratio, motility and distal axon residency, and
markedly accelerating axonal outgrowth.
Importantly, the time courses of these
responses, in which motility was maximized
only 2 hours after mitofusin activation and
axonal outgrowth was markedly accelerated
within 24 hours, but mitochondrial fusion
was corrected only after 48 hours, supported
a causal relationship between mitochondrial
transport and neuronal regrowth (Franco et
al., 2020).
Finally, because de novo DRG axon outgrowth
might be mechanistically distinct from axon
regrowth after injury in CMT2A, Franco et
al. (2020) isolated neonatal cortical neurons
from hMFN2 T105M flox-stop mice and
cultured the neurons in wells connected
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to empty wells by linear microchannels.
Cortical neuron outgrowth resulted in long,
non-branching axons that grew through the
microchannels into the empty wells, wherein
they underwent terminal branching. This
in vitro arrangement mimics in vivo neuron
architecture of soma, linear axon body
and distal branched axon. Because mouse
CMT2A neurons grow very poorly (as in the
above DRG studies), adeno-Cre was used
to induce hMFN2 T105M expression after
the cultured cortical neurons had grown
through the microchannels and developed
complex arborizations (i.e., 10 days in vitro).
In this way, mature CMT2A neurons were
created that subsequently underwent distal
aspiration axotomy, amputating the distal
branched axons while leaving the proximal
linear axons intact. Amputated neurons
were maintained in culture in the presence
or absence of mitofusin activator and early
mitochondrial readouts of fusion (aspect
ratio) and motility (% motile and velocity)
were related to axon regrowth after 3 days.
Mitochondrial aspect ratio was not affected
by axotomy, whereas mitochondrial motility
in CMT2A neurons (already diminished
by half compared to normal neurons
treated identically) was further reduced
after axotomy, but restored by mitofusin
activation. Importantly, axon regrowth in
CMT2A neurons was doubled by mitofusin
activation.
These studies are the first to mechanistically
l i n k m i t o f u s i n a c t i va t i o n , e n h a n c e d
mitochondrial transport to distal regions
of the neuron, and accelerated neuronal
regeneration. The novel in vitro and in
vivo CMT2A disease models employed
in these studies integrated loss of MFN2
function with restoration of function to
demonstrate a central role for mitofusins
in mitochondrial motility. The underlying
principle is that accelerated regeneration
of damaged nerves can be achieved by
facilitating delivery of healthy mitochondria
to, and damaged mitochondria away from,
terminal axon growth areas. Indeed, this
paradigm may apply to other genetic
neurodegenerative diseases, including
amyotrophic lateral sclerosis, Huntington’s
disease, Parkinson’s disease, wherein
abnormalities of mitochondrial structure,
transport and/or function contribute to
observed neuropathology (Knott et al.,
2008). In these conditions we envision a
vicious pathophysiologic cycle wherein

p r i m a r y ge n et i c m u tat i o n s e n co d i n g
diverse proteins that directly or indirectly
damage mitochondria evoke oxidative stress
and mitotoxicity, resulting in additional
mitochondrial damage and a feedback loop
that culminates in metabolic insufficiency
from mitochondrial drop-out and neuronal
death from mitochondrial pathway apoptosis.
According to this scenario, interrupting the
cycle at any point could prove therapeutic.
Thus, interventions like mitofusin activation
t h at p ro m o te ge n e ra l m i to c h o n d r i a l
resistance to an array of noxious insults may
have broad therapeutic utility.
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